| Autor: |
Tomoya Harada, Naoki Uetani, Genki Inui, Hiroki Ishikawa, Yoshihiro Funaki, Miki Takata, Ryota Okazaki, Kosuke Yamaguchi, Masato Morita, Shin Kitatani, Akira Yamasaki |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Respiratory Medicine Case Reports, Vol 49, Iss , Pp 102035- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2213-0071 |
| DOI: |
10.1016/j.rmcr.2024.102035 |
| Popis: |
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported. A 54-year-old woman with endometrial cancer experienced asthma exacerbation, and increased blood eosinophil counts 3 months after pembrolizumab administration. Although asthma exacerbation improved, the resumption of pembrolizumab caused the recurrence of dry cough and hypereosinophilia. The discontinuation of pembrolizumab improved her symptoms. Serum interleukin-5 levels increased during pembrolizumab treatment but decreased upon discontinuation. The blockade of PD-1 and its ligand may exacerbate asthma through eosinophilic inflammation. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
